Solid Phase Transglutaminase Conjugation for Antibody-Drug Precision
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for conjugating moieties to immunoglobulins using transglutaminases lack predictability and efficiency, particularly in achieving high drug-antibody ratios and are not economically scalable.
Innovation Solution
The development of solid phase processes that utilize transglutaminase-mediated conjugation on immobilized antibodies, allowing for high efficiency conjugation to Fc domains with minimal enzyme and drug conjugate usage, and the use of click-chemistry type linkers for high-yield reactions, enabling direct application and reaction on solid supports.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If transglutaminase-mediated conjugation is performed in solution phase, then the conjugation process is simple to operate, but the manufacturing precision and control of conjugation sites are poor
Solution Approach 1:
The patent transitions the conjugation process from solution phase to solid phase by immobilizing antibodies on solid supports. This dimensional change allows precise control of conjugation sites while maintaining operational simplicity through standardized solid phase protocols.
Solution Approach 2:
The patent achieves site-specific conjugation by selecting particular glutamine residues (e.g., Q295, Q297 in Fc domains) as acceptor sites. This local quality approach ensures controlled conjugation at predetermined locations rather than random modification throughout the antibody structure.
2Productivity
If high antibody concentrations are used to improve productivity, then the production efficiency increases, but aggregation and precipitation occur reducing reliability
Solution Approach 1:
By moving to solid phase conjugation, the patent enables use of high antibody concentrations (above 10 mg/ml) that would cause aggregation in solution. The solid support immobilization prevents intermolecular interactions that lead to aggregation, allowing concentrated samples to be processed reliably.
Solution Approach 2:
The patent extracts the antibody from the solution phase and immobilizes it on a solid support. This separation removes the problematic solution environment that causes aggregation at high concentrations, while maintaining antibody accessibility for conjugation.
3Productivity
If transglutaminase is used in large quantities to achieve high conjugation efficiency, then the conjugation rate increases, but the loss of substance and production cost increase
Solution Approach 1:
The patent employs immobilized transglutaminase on the solid support, which catalyzes conjugation repeatedly as linkers are applied. The enzyme serves itself by remaining bound and active throughout the process, eliminating the need for large quantities of enzyme and reducing material loss.
Solution Approach 2:
The transglutaminase is immobilized on the solid support before the conjugation reaction begins. This preliminary preparation allows the enzyme to be in optimal position and conformation for catalysis, increasing efficiency and reducing the amount of enzyme needed.
4Manufacturing precision
If multiple purification steps are performed to remove TGase and other components, then the purity of the final product increases, but the loss of time and production efficiency decrease
Solution Approach 1:
The patent extracts and removes the transglutaminase enzyme from the final product through washing steps after solid phase conjugation. Since the enzyme remains immobilized on the solid support while the conjugated antibody is eluted, a single purification step suffices, saving time compared to multiple purification steps required in solution phase methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves high drug-antibody ratios with controlled conjugation, allowing for high antibody concentrations and efficient production, overcoming issues of aggregation and precipitation, and enabling entirely solid phase processes for antibody-drug conjugate production.
Implementation Method 1
Transglutaminases (TGases) have been exploited for some time in the food industry for their ability to cross-link proteins. TGases have been shown to be capable of conjugating glutamine and lysine residues
Implementation Method 2
TGases have been shown to be capable of conjugating glutamine and lysine residues, including antibodies
Implementation Method 3
Using complementary reactive moieties of Click-chemistry type on the linkers, high yields are achieved
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to solid-support based processess for the functionalization of immunoglobulins through the use of transglutaminase. Also provided are solid support compositions with bound antibody. The methods can be used, for example, in manufacturing processes or in drug screening.